Denys-drash syndrome
Denys-Drash Syndrome (DDS) is a rare genetic disorder characterized by a triad of gonadal dysgenesis, nephropathy, and Wilms' tumor. It is associated with mutations in the WT1 gene, which plays a crucial role in kidney and gonad development.
Clinical Features[edit | edit source]
The clinical features of Denys-Drash Syndrome typically manifest early in life. The most common symptoms include proteinuria, edema, and hypertension, which are indicative of kidney disease. In addition, individuals with DDS often develop Wilms' tumor, a type of kidney cancer that primarily affects children. Gonadal dysgenesis, another hallmark of DDS, leads to ambiguous genitalia and intersex conditions in affected individuals.
Genetics[edit | edit source]
Denys-Drash Syndrome is caused by mutations in the WT1 gene, which is located on chromosome 11. This gene is responsible for the production of a protein that regulates the activity of other genes involved in kidney and gonad development. Mutations in the WT1 gene disrupt this regulatory function, leading to the characteristic features of DDS.
Diagnosis[edit | edit source]
The diagnosis of Denys-Drash Syndrome is based on clinical findings, genetic testing, and histopathology of kidney tissue. Genetic testing can confirm the presence of a WT1 gene mutation, while histopathology can reveal the presence of diffuse mesangial sclerosis, a type of kidney damage that is characteristic of DDS.
Treatment[edit | edit source]
The treatment of Denys-Drash Syndrome is primarily supportive and includes management of kidney disease, treatment of Wilms' tumor, and gender assignment in cases of ambiguous genitalia. Kidney transplantation may be necessary in cases of end-stage kidney disease.
Prognosis[edit | edit source]
The prognosis of Denys-Drash Syndrome is generally poor due to the high risk of kidney failure and Wilms' tumor. Early diagnosis and treatment can improve the prognosis to some extent.
See Also[edit | edit source]
| Denys-drash syndrome Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
